Tylenol Maker Resists Proposed Label Change Linking Medication to Autism Risk in Pregnancy

Kenvue, the manufacturer of Tylenol, is opposing potential changes to the product's safety label that could link its use in pregnancy to an increased risk of autism, citing insufficient evidence from FDA research as a reason for not altering the labeling. The proposed change was sparked by concerns over studies suggesting a possible correlation between acetaminophen, the active ingredient in Tylenol, and the development of autism spectrum disorder (ASD) in children. Kenvue argues that while some research suggests a potential link, more rigorous testing is needed to confirm the findings before such changes can be made to the label. The FDA has yet to announce an official decision on the proposed labeling change.